Israel is considered a relative newcomer to the biotechnology industry, and one Israeli consultant says its biotechnology companies are not attracting enough money from outside the country, Israel's chief scientist is spreading funding across too many new biotech companies and the country lacks enough infrastructure to conduct clinical trials. Ranan Lachman said resources within the government need to be concentrated on the clinical activities required by the most promising companies and that marketing packages from Israeli biotech firms are hurt by a lack of professionalism.

Related Summaries